SCHEMBL600327

SCHEMBL600327

Cc1ccc(S(=O)(=O)O)c(CCCF)c1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TAAR1 Q96RJ0 1/20 0.36
GAA P10253 3/20 0.36
HSD17B10 Q99714 2/20 0.36
MPL P40238 1/20 0.35
AMY1A P0DUB6 1/20 0.34
ALDH1A1 P00352 3/20 0.33
POLB P06746 3/20 0.33
RECQL P46063 2/20 0.33
TDP1 Q9NUW8 2/20 0.33
KMT2A Q03164 2/20 0.33
MAPT P10636 2/20 0.33
MEP1B Q16820 1/20 0.33
KDM4E B2RXH2 1/20 0.33
MEN1 O00255 1/20 0.33
CASP6 P55212 1/20 0.33
ELAVL1 Q15717 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
RAPGEF4 Q8WZA2 1/20 0.33
MYC P01106 1/20 0.33
LMNA P02545 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6968755 0.94 TAAR1 (0.34) TAAR1GAAHSD17B10MPLAMY1A
SCHEMBL9562138 0.94 TAAR1 (0.34) TAAR1GAAHSD17B10MPLAMY1A
SCHEMBL8496556 0.94 TAAR1 (0.34) TAAR1GAAHSD17B10MPLAMY1A
SCHEMBL242277 0.90 TAAR1 (0.38) TAAR1GAAHSD17B10MPLAMY1A
SCHEMBL816601 0.90 GAA (0.39) TAAR1GAAHSD17B10MPLAMY1A
SCHEMBL30723203 0.90 GAA (0.39) TAAR1GAAHSD17B10MPLAMY1A
SCHEMBL5718625 0.90 GAA (0.39) TAAR1GAAHSD17B10MPLAMY1A
SCHEMBL29975298 0.90 GAA (0.39) TAAR1GAAHSD17B10MPLAMY1A
SCHEMBL8082255 0.88 GAA (0.38) TAAR1GAAHSD17B10MPLAMY1A
SCHEMBL8084715 0.88 GAA (0.38) TAAR1GAAHSD17B10MPLAMY1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12544463-B2 Deuterium substituted positron emission tomography (PET) imaging agents and their pharmacological application FIVE ELEVEN PHARMA INC. (US) 2026-02-10 US disclosed
EP-4663637-A2 NOVEL DEUTERIUM SUBSTITUTED POSITRON EMISSION TOMOGRAPHY (PET) IMAGING AGENTS AND THEIR PHARMACOLOGICAL APPLICATION Five Eleven Pharma Inc. (US) 2025-12-17 EP disclosed
CN-114539243-B Novel deuterium-substituted Positron Emission Tomography (PET) imaging agent and pharmacological application thereof 五一一制药股份有限公司 2024-01-30 CN disclosed
CN-115536580-A Deuterium substituted Positron Emission Tomography (PET) imaging agents and their pharmacological use 五一一制药股份有限公司 2022-12-30 CN disclosed
CN-110678465-B Novel deuterium-substituted Positron Emission Tomography (PET) imaging agents and their pharmacological use 五一一制药股份有限公司 2022-12-02 CN disclosed
CN-111517902-B Aerobic oxidation system containing sulfinic acid, sulfonic acid or derivatives thereof and photo-oxidation promoting method thereof 清华大学 2022-06-14 CN disclosed
CN-114539243-A Novel deuterium-substituted Positron Emission Tomography (PET) imaging agents and their pharmacological use 五一一制药股份有限公司 2022-05-27 CN disclosed
US-20210346526-A1 NOVEL DEUTERIUM SUBSTITUTED POSITRON EMISSION TOMOGRAPHY (PET) IMAGING AGENTS AND THEIR PHARMACOLOGICAL APPLICATION FIVE ELEVEN PHARMA INC. 2021-11-11 US disclosed
US-11071794-B2 Deuterium substituted positron emission tomography (PET) imaging agents and their pharmacological application FIVE ELEVEN PHARMA INC. (US) 2021-07-27 US disclosed
US-10912849-B2 Deuterium substituted positron emission tomography (PET) imaging agents and their pharmacological application FIVE ELEVEN PHARMA INC. (US) 2021-02-09 US disclosed
WO-2010049819-A1 USE OF 7-CHLORO-N,N,5-TRIMETHYL-4-OXO-3-PHENYL-3,5-DIHYDRO-4H-PYRIDAZINO[4,5-B]INDOLE-1-ACETAMIDE AS A BIOMARKER OF PERIPHERAL BENZODIAZEPINE RECEPTOR LEVELS SANOFI-AVENTIS (FR) 2010-05-06 WO disclosed
EP-2012833-A2 RADIOLABELED DIHYDROTETRABENAZINE DERIVATIVES AND THEIR USE AS IMAGING AGENTS The Trustees Of The University Of Pennsylvania (US) 2009-01-14 EP disclosed
US-20080050312-A1 Radiolabeled dihydrotetrabenazine derivatives and their use as imaging agents THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 2008-02-28 US disclosed
WO-2007130365-A2 RADIOLABELED DIHYDROTETRABENAZINE DERIVATIVES AND THEIR USE AS IMAGING AGENTS THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 2007-11-15 WO disclosed
US-20060120956-A1 Imaging agents comprising barbituric acid derivatives KOPKA KLAUS 2006-06-08 US disclosed
EP-1549317-A1 IMPROVED IMAGING AGENTS COMPRISING BARBITURIC ACID DERIVATIVES GE Healthcare Limited (GB) 2005-07-06 EP disclosed
US-20040097522-A1 Triazolopyrimidines BAYER CROPSCIENCE AG (DE) 2004-05-20 US disclosed
WO-2004032936-A1 IMPROVED IMAGING AGENTS COMPRISING BARBITURIC ACID DERIVATIVES AMERSHAM PLC (GB) 2004-04-22 WO disclosed
EP-1349859-A2 TRIAZOLOPYRIMIDINES Bayer CropScience AG (DE) 2003-10-08 EP disclosed
WO-2002050077-A2 TRIAZOLOPYRIMIDINES BAYER CROPSCIENCE AG (DE) 2002-06-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11071794-B2 Deuterium substituted positron emission tomography (PET) imaging agents and their pharmacological application SLC18A2, SLC6A3, SLC6A2 TAAR1 208/4885GAA 492/4885HSD17B10 616/4885
US-12544463-B2 Deuterium substituted positron emission tomography (PET) imaging agents and their pharmacological application SLC18A2, SLC6A3, SLCO1B3 TAAR1 220/4885GAA 2784/4885HSD17B10 1530/4885
US-20210346526-A1 NOVEL DEUTERIUM SUBSTITUTED POSITRON EMISSION TOMOGRAPHY (PET) IMAGING AGENTS AND THEIR PHARMACOLOGICAL APPLICATION SLC18A2, SLC6A3, SLC6A2 TAAR1 181/4885GAA 469/4885HSD17B10 631/4885
US-10912849-B2 Deuterium substituted positron emission tomography (PET) imaging agents and their pharmacological application SLC18A2, SLC6A3, SLC6A2 TAAR1 208/4885GAA 492/4885HSD17B10 616/4885
US-20060120956-A1 Imaging agents comprising barbituric acid derivatives CA5A, GABRA5, CA5B TAAR1 673/4885GAA 2029/4885HSD17B10 2709/4885
US-20080050312-A1 Radiolabeled dihydrotetrabenazine derivatives and their use as imaging agents SLC18A2, SLC18A3, SLC6A2 TAAR1 133/4885GAA 140/4885HSD17B10 471/4885
US-20040097522-A1 Triazolopyrimidines Q6ZSR9, CYP4X1, DDT TAAR1 6/4885GAA 2506/4885HSD17B10 4466/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.